We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Acadia Draws FDA Deficiency Letter for Nuplazid
San Diego, Calif.-based Acadia Pharmaceuticals has received a notification of deficiencies from the FDA regarding its supplemental New Drug Application (sNDA) for Nuplazid (pimavanserin), an anti-psychosis drug being reviewed for treating dementia-related hallucinations and delusions.